Covid-19 impact: Indian firms look to fill in for US' Famotidine crunch

Some see this as an opportunity for Indian firms like Alembic, Aurobindo who make both the bulk drug and the formulation

After common antacid drug Famotidine shot to the limelight for being a potential treatment for Covid-19, the demand surge for the drug has led to a shortage in the US.
 

Some see this as an opportunity for Indian firms like Alembic and Aurobindo that make both the bulk drug and the formulation.

Meanwhile, the central government, too, has taken note of the demand and decided to undertake a stock-taking exercise for the drug in case of a sudden export demand, besides procuring for Jan Aushadhi stores.
 

So far, there has not been any significant jump in demand for the over-the-counter (OTC)